Extracellular vesicles from human urine-derived stem cells delay aging through the transfer of PLAU and TIMP1
- Acta Pharm Sin B. 2024 Mar;14(3):1166-1186. doi: 10.1016/j.apsb.2023.12.009.
- 1. Department of Orthopedics, Movement System Injury and Repair Research Center, Xiangya Hospital, Central South University, Changsha 410008, China.
- 2. Hunan Key Laboratory of Angmedicine, Changsha 410008, China.
- 3. Xiangya School of Nursing, Central South University, Changsha 410013, China.
- 4. Department of Pediatric Orthopedics, Hunan Children's Hospital, University of South China, Changsha 410007, China.
- 5. Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.
- 6. School of Nursing, Xinjiang Medical University, Urumqi, Xinjiang 830000, China.
- 7. Department of Rehabilitation, Xiangya Hospital, Central South University, Changsha 410008, China.
- 8. National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China.
Aging increases the risks of various diseases and the vulnerability to death. Cellular senescence is a hallmark of aging that contributes greatly to aging and aging-related diseases. This study demonstrates that extracellular vesicles from human urine-derived stem cells (USC-EVs) efficiently inhibit cellular senescence in vitro and in vivo. The intravenous injection of USC-EVs improves cognitive function, increases physical fitness and bone quality, and alleviates aging-related structural changes in different organs of senescence-accelerated mice and natural aging mice. The Anti-aging effects of USC-EVs are not obviously affected by the USC donors' ages, genders, or health status. Proteomic analysis reveals that USC-EVs are enriched with plasminogen activator urokinase (PLAU) and tissue inhibitor of metalloproteinases 1 (TIMP1). These two proteins contribute importantly to the anti-senescent effects of USC-EVs associated with the inhibition of Matrix Metalloproteinases, cyclin-dependent kinase inhibitor 2A (P16INK4a), and cyclin-dependent kinase inhibitor 1A (P21cip1). These findings suggest a great potential of autologous USC-EVs as a promising Anti-aging agent by transferring PLAU and TIMP1 proteins.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Cancer